vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC

This trial will provide the maximum tolerated dose for radiation therapy for liver tumors and describe the toxicity profile using the vGRID therapy technique. Based on trials using this type of radiation in other cancers demonstrating low toxicity rates even with very high radiation doses and high efficacy, it is likely that vGRID therapy in this trial will be well tolerated and allow dose escalation beyond currently common doses for liver tumors.

Trial Details

NCT ID
NCT05727787
Phase
NA
Sponsor
University of Kansas Medical Center
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Stereotactic Body Radiation Treatment
Locations (sample)
  • Kansas City, Kansas, United States|39.11417,-94.62746

Key Eligibility Criteria

  • Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written in…
  • Males and females age ≥ 18 years.
  • ECOG Performance Status 0 - 1
  • Histologically confirmed hepatocellular carcinoma (HCC) or mixed HCC and cholangiocarcinoma either locally advanced or metastatic.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →